Lifecore Biomedical to Be Acquired by Webster Equity Partners
LFCR sits 19% above its 52-week low of $3.625.
Summary
Lifecore Biomedical has agreed to be acquired by Webster Equity Partners. Common stockholders will receive $6.28 per share in cash at closing, and Series A preferred stockholders will receive the required conversion amount per share in cash. Stockholders may receive up to $9.67 per common equivalent in combined cash and contingent value rights (CVR) upon full performance milestone payments, which include $30M for 2028, $45M for 2029, and $85M for 2030. The deal provides an exit for shareholders amid the company's liquidity crisis, which included a $50.2 million preferred stock redemption due December 28 that it could not fund without lender consent. The acquisition likely resolves activist investor pressure from 22NW Fund and Legion Partners, who had demanded cash redemption of their Series A Preferred Stock. The acquisition is a material positive for shareholders, as it offers a premium to the current $4.30 stock price and removes the overhang of the preferred stock redemption. The merger agreement includes termination fees of $7.47M (go-shop), $9.96M (company), and $16.18M (reverse).
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The merger agreement includes CVR milestone payments of $30M for 2028, $45M for 2029, and $85M for 2030, with termination fees of $7.47M (go-shop), $9.96M (company), and $16.18M (reverse).
At the time of this announcement, LFCR was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159M. The 52-week trading range was $3.63 to $8.98. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.